AQP4 and neuromyelitis optica: However, in June 2020, inebilizumab received global approval in the USA for the treatment of neuromyelitis optica spectrum disorder in adult patients who are seropositive for IgG autoantibodies against aquaporin-4 (AQP4-IgG) [94].